By Jasmine Li
Pulse Biosciences reported positive preliminary results from its clinical study of a treatment for benign thyroid nodules.
The Miami-based company's Nanosecond Pulsed Field Ablation technology reduced nodule sizes on average by more than 50%, it said on Thursday.
The 30-patient feasibility study also found that the technology provided symptomatic relief within the first month of treatment, and showed no evidence of residual fibrosis or scarring, the company said.
These results suggest that nano-PFA energy can provide symptomatic relief to patients with benign thyroid nodules across the first month after the treatment, Chief Executive Burke Barrett said.
The company intends to commence a pivotal trial in mid-2025 designed to support a specific labeling indication to commercialize the system in the U.S., Barrett said.
Write to Jasmine Li at jasmine.li@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
October 31, 2024 15:12 ET (19:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.